Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health disorders. The company’s neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms of action, including muscarinic M1/M4 agonism and next-generation NMDA antagonism.